TY - JOUR
T1 - An update on autoantibodies in scleroderma
AU - Mecoli, Christopher A.
AU - Casciola-Rosen, Livia
N1 - Publisher Copyright:
© 2018 Lippincott Williams and Wilkins. All rights reserved.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Purpose of reviewNew research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism.Recent findingsA growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes.SummaryContinued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer-scleroderma relationship.
AB - Purpose of reviewNew research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism.Recent findingsA growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes.SummaryContinued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer-scleroderma relationship.
KW - antibodies
KW - phenotype
KW - scleroderma
UR - http://www.scopus.com/inward/record.url?scp=85067537802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067537802&partnerID=8YFLogxK
U2 - 10.1097/BOR.0000000000000550
DO - 10.1097/BOR.0000000000000550
M3 - Review article
C2 - 30148799
AN - SCOPUS:85067537802
SN - 1040-8711
VL - 30
SP - 548
EP - 553
JO - Current opinion in rheumatology
JF - Current opinion in rheumatology
IS - 6
ER -